MP12-11 NEOADJUVANT THERAPY IN THE MANAGEMENT OF LOCAL RETROPERITONEAL RECURRENCE OF RENAL CELL CARCINOMA AFTER RADICAL NEPHRECTOMY

Abstract

You have accessJournal of UrologyCME1 May 2022MP12-11 NEOADJUVANT THERAPY IN THE MANAGEMENT OF LOCAL RETROPERITONEAL RECURRENCE OF RENAL CELL CARCINOMA AFTER RADICAL NEPHRECTOMY Jiwei Huang, Yueming Wang, Cuijian Zhang, Xiaoyi Hu, Ping Wang, Guohai Shi, Jin Zhang, Wen Kong, Yonghui Chen, Yiran Huang, Dingwei Ye, Dan Xia, Jianming Guo, Zhisong He, and Wei Xue Jiwei HuangJiwei Huang More articles by this author , Yueming WangYueming Wang More articles by this author , Cuijian ZhangCuijian Zhang More articles by this author , Xiaoyi HuXiaoyi Hu More articles by this author , Ping WangPing Wang More articles by this author , Guohai ShiGuohai Shi More articles by this author , Jin ZhangJin Zhang More articles by this author , Wen KongWen Kong More articles by this author , Yonghui ChenYonghui Chen More articles by this author , Yiran HuangYiran Huang More articles by this author , Dingwei YeDingwei Ye More articles by this author , Dan XiaDan Xia More articles by this author , Jianming GuoJianming Guo More articles by this author , Zhisong HeZhisong He More articles by this author , and Wei XueWei Xue More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000002534.11AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Local retroperitoneal recurrence (RPR) after radical nephrectomy (RN) is rare in patients with renal cell carcinoma (RCC); however, it is associated with poor prognosis and lacks standard treatment. This study aimed to assess oncological outcomes and prognostic factors of patients that underwent targeted therapy for RPR after RN, and to evaluate the role of neoadjuvant targeted therapy in this context. METHODS: This was a retrospective multi-center study of 85 patients with RPR treated with targeted therapy for RPR after RN (2008-2020). Clinical and pathological characteristics were reported using descriptive statistics. Cancer-specific survival (CSS) was examined using the Cox proportional hazards model. RESULTS: The median follow-up time was 50 months (95% confidence interval [CI]: 33.3-66.7) after the RPR diagnosis. The median CSS was 96 months in the neoadjuvant targeted therapy followed by surgical resection group and 42 months (95% CI: 28.8-55.2) in the targeted therapy alone group (P = 0.001). In multivariate analysis, International Metastatic RCC Database Consortium classification poor-risk, number of recurrence sites, and surgical resection were independent predictors of CSS. CONCLUSIONS: Neoadjuvant targeted therapy may increase the feasibility of tumor resection for RPR after RN. Patients who underwent surgical resection following neoadjuvant targeted therapy had better CSS than those treated with targeted therapy alone. Source of Funding: This study was supported by grants from the Natural Science Foundation of Shanghai (21ZR1438900), Incubating Program for Clinical Research and Innovation of Renji Hospital (PYXJS16-008 and PYIII20-07), and Basic Oncology Research Program from the Bethune Charitable Foundation (BCF-NH-ZL-20201119-024) © 2022 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 207Issue Supplement 5May 2022Page: e171 Advertisement Copyright & Permissions© 2022 by American Urological Association Education and Research, Inc.MetricsAuthor Information Jiwei Huang More articles by this author Yueming Wang More articles by this author Cuijian Zhang More articles by this author Xiaoyi Hu More articles by this author Ping Wang More articles by this author Guohai Shi More articles by this author Jin Zhang More articles by this author Wen Kong More articles by this author Yonghui Chen More articles by this author Yiran Huang More articles by this author Dingwei Ye More articles by this author Dan Xia More articles by this author Jianming Guo More articles by this author Zhisong He More articles by this author Wei Xue More articles by this author Expand All Advertisement PDF DownloadLoading ...